Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
about
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Cancer immunotherapy: the beginning of the end of cancer?Big Data Offers Novel Insights for Oncolytic Virus ImmunotherapyOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeViro-immune therapy: A new strategy for treatment of pancreatic cancerEngineering opportunities in cancer immunotherapyReplication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataHigh-throughput screening to enhance oncolytic virus immunotherapyCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesPathways and therapeutic targets in melanomaTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial Watch:: Oncolytic viruses for cancer therapyOncolytic viruses as anticancer vaccinesOncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpointsEngineering New Approaches to Cancer VaccinesHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesToward understanding and exploiting tumor heterogeneityCombined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infectionPrime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesRevisiting the hallmarks of cancer.Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Oncolytic viruses: From bench to bedside with a focus on safety.Novel immune checkpoint blocker approved for the treatment of advanced melanomaTherapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITKRegional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.Gene and cell therapy for pancreatic cancer.Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer modelsOncolysis by paramyxoviruses: preclinical and clinical studies.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Inhibitory receptors as targets for cancer immunotherapyInhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesThe tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
P2860
Q26747695-4445ADEF-42D3-4825-9527-C4F5E054312FQ26752277-D23C3527-1B06-41E4-A7F0-851B5C1F6CE8Q26767209-F5429990-9DC1-49C5-910C-53DC6A128A1FQ26769977-1054F079-8C6A-4A7C-B98B-2B804050C0CBQ26774641-23E52542-D0F2-4780-8D1F-6CD884B14E2AQ26776373-A0CCC1BA-6542-4F5B-8820-4440D79BEAB2Q26801501-379E724F-EE68-4B96-95F6-F2F7C32F212CQ26823674-5A5CF980-5E58-4726-8D90-35FFC6A298B0Q26863779-F7F2DEBB-BE7F-4A20-8C1C-BC9B4AECCE22Q26865736-655D7522-52E2-4E88-A049-DE5364848603Q26996518-8334E892-5019-4AE4-96F4-DA22FD6BAFD5Q27021951-FCABA20E-1831-4B50-B96E-E58D16E76BE0Q27025600-FC14E4B2-C3CF-4B17-B103-6695966688DDQ28083515-E5F7F86A-A1A6-4B49-82E1-805F89DDADEFQ28085563-FA031C41-7F2A-453E-B215-54B806826E68Q28086999-749D5D33-D4B4-4AEB-B109-9A45917F81BBQ28395597-2FE51907-A03E-43B0-A982-9E0E81B8CBB8Q28603034-DB992305-4336-41D4-A20A-D8BBB3160A16Q28817152-B24B94C4-4986-4F66-A450-27E6A1E516C6Q33551626-71E29DF3-36A5-40E1-8F86-32FE35165B47Q33679505-90A27598-CAEE-4D31-8F6A-7E05FC200AFEQ33732986-90B44A20-D61F-42AF-B363-8C2A2ECCE022Q33762986-750D9CAE-1665-47BF-AEBF-DC5BC8833E57Q33899522-E6612E4F-20B2-4AB9-9049-C473FB7BF3EDQ34044071-A4FB8EED-7754-4036-8FB2-F2BF3875EAECQ34936394-2D5FC0F2-CD39-48CF-865A-DF504433EEBFQ35156866-452262CC-4380-41AB-BDF1-1D2E76B9E386Q35216278-9A24C1A3-89AA-471A-B81D-9FE50D5BB46FQ35329190-68870CB0-A62C-48E0-B8D5-78C280F21958Q35417571-FBB1354E-D33A-46A9-B215-3E5F87AB8C65Q35541787-D8896C5F-9B38-405F-A3E4-F780A6C0CAE3Q35587389-28219068-AC61-46BC-837F-3B5DC9AC8182Q35861933-07CB73C3-C65A-49AE-9DE5-16ECD59B9B33Q35861936-93486BAC-9DAC-4CFE-8A0E-538D8780D34AQ35995373-63FE99AC-67F2-4914-8BDA-061824F8F382Q36015063-D5D98FA3-115A-46E1-AED3-589B9B090BDCQ36050315-E472970A-DAF0-4822-9635-6A6553BE2F30Q36301061-1266AB86-7509-4940-BAFC-4179AB00C7ADQ36308045-6DEC8AA0-D340-4FFC-BE47-C59E9D12E5F8Q36378248-2BD7EA07-DB7B-4C23-9DB3-9422F36171FC
P2860
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Localized oncolytic virotherap ...... kpoint blockade immunotherapy.
@ast
Localized oncolytic virotherap ...... kpoint blockade immunotherapy.
@en
type
label
Localized oncolytic virotherap ...... kpoint blockade immunotherapy.
@ast
Localized oncolytic virotherap ...... kpoint blockade immunotherapy.
@en
altLabel
Localized oncolytic virotherap ...... ckpoint blockade immunotherapy
@en
prefLabel
Localized oncolytic virotherap ...... kpoint blockade immunotherapy.
@ast
Localized oncolytic virotherap ...... kpoint blockade immunotherapy.
@en
P2093
P2860
P50
P1476
Localized oncolytic virotherap ...... kpoint blockade immunotherapy.
@en
P2093
Dmitriy Zamarin
Jedd D Wolchok
Joon Seok Park
Rikke B Holmgaard
Sumit K Subudhi
Taha Merghoub
P2860
P304
P356
10.1126/SCITRANSLMED.3008095
P407
P577
2014-03-01T00:00:00Z